ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
CU
Copenhagen University Hospital – Herlev at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Copenhagen University Hospital – Herlev takes part in 9 sessions at ESMO 2026 in Madrid. Its work at the meeting spans several cancer types, with a focus on immunotherapy and patient outcomes. It examines survival after stopping immune checkpoint treatment in melanoma and care approaches for pancreatic cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
CU Copenhagen University Hospital – Herlev Herlev, Denmark | |
Public university hospital in Herlev, near Copenhagen, Denmark, home to a national centre for cancer immune therapy. | Poster Fri Oct 23 13:00–15:00 Talk Sat Oct 24 11:44–11:51 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Abstract Sat Oct 24 16:42–16:54 Invited Discussant LBA1 Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Poster Sun Oct 25 12:00–12:45 Early specialized palliative care in advanced pancreatic cancer (EarlyCarePan): A nationwide Danish randomized trial Gastrointestinal cancersNursing & supportive care Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Real world outcomes in small bowel adenocarcinoma patients from eastern Denmark Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Poster Sun Oct 25 12:00–12:45 Talk Sun Oct 25 14:45–15:05 Acute and late toxicities of TILs and TCR therapy in solid tumours Nursing & supportive care Chair Sun Oct 25 14:45–16:15 Toxicities of immunotherapies beyond immune checkpoints Nursing & supportive care Poster Mon Oct 26 12:00–12:45 |
Find decision makers at Copenhagen University Hospital – Herlev
Tell us what you sell and we’ll find the people at Copenhagen University Hospital – Herlev most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction